CareLit · DOI-Nachweis · Nuklearmedizin - NuclearMedicine
177Lu-based radioligand therapy: A retrospective multicenter analysis to calculate the effective half-life and follow-up dose for the public
DOI 10.1055/a-2784-7468
Bibliografische Angaben
Nachweis in CareLit
Autor:innenChristian Schütze, Markus Borowski, Martin Freesmeyer, Robert Freudenberg, Heribert Hänscheid, Jens Kurth, Marc Rudi Linde, Lara-Christiane Militzer, Bernhard Sattler, Tabea Nikola Schmidt, Paul Soubiran, Mathias Steffner, Lars Stegger, Carsten Wanke, Christian Kühnel
ZeitschriftNuklearmedizin - NuclearMedicine
Ausgabe02/2026
Jahrgang / SeitenJg. 65 · S. 60-68
Kernaussage aus der Literatur
Abstract-Vorschau
AbstractThe study investigated routinely used radiopharmaceuticals containing lutetium-177 (177Lu), providing reference values for their effective half-life (T1/2,eff). So far, no guidelines regarding discharging this patients exist, are essential to ensure radiation protection of the public. This study contributes to the development of binding discharge criteria regarding 177Lu therapies.This retrospective multicen…
Zitieren
Zitierempfehlung
Christian Schütze, Markus Borowski, Martin Freesmeyer, Robert Freudenberg, Heribert Hänscheid, Jens Kurth, Marc Rudi Linde, Lara-Christiane Militzer, Bernhard Sattler, Tabea Nikola Schmidt, Paul Soubiran, Mathias Steffner, Lars Stegger, Carsten Wanke, Christi… (2026) 177Lu-based radioligand therapy: A retrospective multicenter analysis to calculate the effective half-life and follow-up dose for the public. Nuklearmedizin - NuclearMedicine, 65 (02), 60-68. https://doi.org/10.1055/a-2784-7468
Mit CareLit weiterarbeiten